Welcome to the 2nd European Patient Innovation Summit (EPIS 2017) – Realising the connection of digital technologies. Building upon the success and key learnings of the inaugural 2016 Summit, Novartis has continued to collaborate closely with a number of Europe’s leading patient organisations in order to deliver this year’s event. Using the latest digital technologies, the […]
Global Hybrid Educational meeting organized by Novartis Pharma AG with life broadcast via CGRP forum. Globally renowned experts share the latest in #Mirgaine research. http://www.cgrpforum.org/migraine-science-day/ #MigraineAwareness
Migraine Science Day Scientific Hybrid Standalone- Novartis Read More »
Phase II 20120295 study of AMG 334 met primary endpoint, confirming efficacy and safety in patients with chronic migraine over 12 weeks of treatment Migraine is a leading cause of disability, affecting more than 10% of people worldwide – within the overall migraine population, people with chronic migraine experience the greatest impact on daily activities
At this meeting Elena Ruiz de la Torre will spend Apr. 45 minutes talking about EMHA as an organisation, and how she sees they can work together with the Nordic countries.
Meeting with Novartis in Tallin Read More »
